Maria Bragança, Inês Barreto, Henrique Rodrigues, Ana Mendes, Carlos Lopes
{"title":"严重哮喘,生物过敏和无效:克服tezepelumab的治疗障碍。","authors":"Maria Bragança, Inês Barreto, Henrique Rodrigues, Ana Mendes, Carlos Lopes","doi":"10.1080/02770903.2025.2552744","DOIUrl":null,"url":null,"abstract":"<p><p>Severe asthma is a heterogeneous disease involving multiple inflammatory pathways, with significant therapeutic challenges. Biologic therapies targeting T2 inflammation improve outcomes but may, in rare cases, trigger hypersensitivity reactions due to anti-drug antibodies, excipients, or protein structure. Additionally, some patients exhibit suboptimal or no response. Tezepelumab, a thymic stromal lymphopoietin inhibitor, offers a novel upstream approach, addressing diverse endotypes.</p><p><p>We present a 30-year-old female with severe T2-high asthma, multiple allergies, and poor disease control despite optimal therapy. She experienced an allergic reaction with omalizumab and dupilumab and had inadequate response to benralizumab. Enrolled in an early access program for tezepelumab, she showed remarkable clinical improvement, with significant FEV1 increase and FeNO reduction, allowing discontinuation of systemic corticosteroids and supplemental oxygen.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-5"},"PeriodicalIF":1.3000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Severe asthma, biologic hypersensitivity and inefficacy: overcoming treatment barriers with tezepelumab.\",\"authors\":\"Maria Bragança, Inês Barreto, Henrique Rodrigues, Ana Mendes, Carlos Lopes\",\"doi\":\"10.1080/02770903.2025.2552744\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Severe asthma is a heterogeneous disease involving multiple inflammatory pathways, with significant therapeutic challenges. Biologic therapies targeting T2 inflammation improve outcomes but may, in rare cases, trigger hypersensitivity reactions due to anti-drug antibodies, excipients, or protein structure. Additionally, some patients exhibit suboptimal or no response. Tezepelumab, a thymic stromal lymphopoietin inhibitor, offers a novel upstream approach, addressing diverse endotypes.</p><p><p>We present a 30-year-old female with severe T2-high asthma, multiple allergies, and poor disease control despite optimal therapy. She experienced an allergic reaction with omalizumab and dupilumab and had inadequate response to benralizumab. Enrolled in an early access program for tezepelumab, she showed remarkable clinical improvement, with significant FEV1 increase and FeNO reduction, allowing discontinuation of systemic corticosteroids and supplemental oxygen.</p>\",\"PeriodicalId\":15076,\"journal\":{\"name\":\"Journal of Asthma\",\"volume\":\" \",\"pages\":\"1-5\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Asthma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/02770903.2025.2552744\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02770903.2025.2552744","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
Severe asthma, biologic hypersensitivity and inefficacy: overcoming treatment barriers with tezepelumab.
Severe asthma is a heterogeneous disease involving multiple inflammatory pathways, with significant therapeutic challenges. Biologic therapies targeting T2 inflammation improve outcomes but may, in rare cases, trigger hypersensitivity reactions due to anti-drug antibodies, excipients, or protein structure. Additionally, some patients exhibit suboptimal or no response. Tezepelumab, a thymic stromal lymphopoietin inhibitor, offers a novel upstream approach, addressing diverse endotypes.
We present a 30-year-old female with severe T2-high asthma, multiple allergies, and poor disease control despite optimal therapy. She experienced an allergic reaction with omalizumab and dupilumab and had inadequate response to benralizumab. Enrolled in an early access program for tezepelumab, she showed remarkable clinical improvement, with significant FEV1 increase and FeNO reduction, allowing discontinuation of systemic corticosteroids and supplemental oxygen.
期刊介绍:
Providing an authoritative open forum on asthma and related conditions, Journal of Asthma publishes clinical research around such topics as asthma management, critical and long-term care, preventative measures, environmental counselling, and patient education.